Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 13/20 | 0.84 |
| ▸ | NPC1 | O15118 | 12/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.84 |
| ▸ | MAPT | P10636 | 5/20 | 0.84 |
| ▸ | HPGD | P15428 | 2/20 | 0.84 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.78 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.78 |
| ▸ | RELA | Q04206 | 2/20 | 0.78 |
| ▸ | PKM | P14618 | 2/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | CASP3 | P42574 | 6/20 | 0.75 |
| ▸ | SENP7 | Q9BQF6 | 6/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.75 |
| ▸ | MEN1 | O00255 | 5/20 | 0.75 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.74 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6848444 | 0.91 | NPC1 (1.00) | RAB9ANPC1SMN1; SMN2MAPTHPGD | |
| SCHEMBL8768779 | 0.88 | RAB9A (0.82) | RAB9ANPC1SMN1; SMN2MAPTHPGD | |
| SCHEMBL108116 | 0.88 | NPC1 (1.00) | RAB9ANPC1SMN1; SMN2MAPTNFKB1 | |
| SCHEMBL4727186 | 0.87 | RAB9A (0.81) | RAB9ANPC1SMN1; SMN2MAPTHPGD | |
| SCHEMBL19092878 | 0.86 | NPC1 (0.74) | RAB9ANPC1SMN1; SMN2MAPTHPGD | |
| SCHEMBL2971586 | 0.85 | RAB9A (0.78) | RAB9ANPC1SMN1; SMN2MAPTHPGD | |
| SCHEMBL11238457 | 0.85 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2MAPTHPGD | |
| SCHEMBL1687778 | 0.85 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2MAPTNFKB1 | |
| SCHEMBL10192037 | 0.85 | NPC1 (0.85) | RAB9ANPC1SMN1; SMN2MAPTHPGD | |
| SCHEMBL7293767 | 0.85 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2MAPTNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| WO-2011020849-A1 | CYTOHESIN INHIBITORS | RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT (DE) | 2011-02-24 | — | — | WO | disclosed |
| EP-2286808-A1 | Cytohesin inhibitors | Rheinische Friedrich-Wilhelms Universität (DE) | 2011-02-23 | — | — | EP | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2007084413-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | RAB9A 3975/4885NPC1 297/4885SMN1; SMN2 4525/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | RAB9A 2829/4885NPC1 87/4885SMN1; SMN2 3609/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | RAB9A 2829/4885NPC1 87/4885SMN1; SMN2 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.